<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Johnson &amp; Johnson</title>
	<atom:link href="http://www.tapanray.in/tag/johnson-johnson/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Corporate Branding In Pharma: An Evolving Strategy In The Emerging Scenario</title>
		<link>http://www.tapanray.in/corporate-branding-in-pharma-an-evolving-strategy-in-the-emerging-scenario/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=corporate-branding-in-pharma-an-evolving-strategy-in-the-emerging-scenario</link>
		<comments>http://www.tapanray.in/corporate-branding-in-pharma-an-evolving-strategy-in-the-emerging-scenario/#comments</comments>
		<pubDate>Mon, 15 Jun 2015 00:00:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Abbott. Pfizer]]></category>
		<category><![CDATA[Apple]]></category>
		<category><![CDATA[Biogen]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Corporate Branding]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6709</guid>
		<description><![CDATA[Pharma advertisements in the mass media do not appear too frequently in India, for various reasons. Though few and far between, whenever these appear are mostly blunt and boring. In that context, an interesting advertisement of a global pharma major &#8230; <a href="http://www.tapanray.in/corporate-branding-in-pharma-an-evolving-strategy-in-the-emerging-scenario/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/corporate-branding-in-pharma-an-evolving-strategy-in-the-emerging-scenario/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Alarming Incidence of Cancer: Fragile Infrastructure: Escalating Drug Prices</title>
		<link>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices</link>
		<comments>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/#comments</comments>
		<pubDate>Mon, 28 Jul 2014 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[alarming]]></category>
		<category><![CDATA[ASCO]]></category>
		<category><![CDATA[Astellas Pharma]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Catering]]></category>
		<category><![CDATA[Celgene]]></category>
		<category><![CDATA[chemicals]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[escalating]]></category>
		<category><![CDATA[evaluate]]></category>
		<category><![CDATA[fact]]></category>
		<category><![CDATA[Fertilizers]]></category>
		<category><![CDATA[fragile]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[incidence]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[intas]]></category>
		<category><![CDATA[Ipca]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[memorial]]></category>
		<category><![CDATA[Merck & Co]]></category>
		<category><![CDATA[Ministers]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reliance Life Science]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[sheet]]></category>
		<category><![CDATA[Sloan]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Zydus Cadila]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5672</guid>
		<description><![CDATA[According to the &#8216;Fact-Sheet 2014&#8242; of the World Health Organization (WHO), cancer cases would rise from 14 million in 2012 to 22 million within the next two decades. It is, therefore, no wonder that cancers figured among the leading causes &#8230; <a href="http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/alarming-incidence-of-cancer-fragile-infrastructure-escalating-drug-prices/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>After Mollycoddling China Cracks Down on Pharma MNCs&#8230;But Why Now?</title>
		<link>http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now</link>
		<comments>http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/#comments</comments>
		<pubDate>Mon, 22 Jul 2013 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[aeon]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Anathema]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Baxter]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Chen]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Chinese]]></category>
		<category><![CDATA[clampdown]]></category>
		<category><![CDATA[contaminated]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[crackdown]]></category>
		<category><![CDATA[Danone]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[Dragon]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[enforced]]></category>
		<category><![CDATA[exemplary]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[grip]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[harsh]]></category>
		<category><![CDATA[hazards]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[land]]></category>
		<category><![CDATA[Major]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[meat]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[milk]]></category>
		<category><![CDATA[mollycoddling]]></category>
		<category><![CDATA[monopolistic]]></category>
		<category><![CDATA[Nestle]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[NovoNordisk]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[powder]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[principle]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rat]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[staggering]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tightening]]></category>
		<category><![CDATA[violations]]></category>
		<category><![CDATA[Zu]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2948</guid>
		<description><![CDATA[In tandem with exemplary growth in the healthcare sector, China has started confronting with some consequential hazards in form of serious regulatory violations involving, besides many others, hospitals, pharmaceutical pricing and food and drug safety, which reportedly include contaminated milk powder and &#8230; <a href="http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/after-mollycoddling-china-cracks-down-on-pharma-mncs-but-why-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
